$TTRX

Turn Therapeutics Inc. (TTRX) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. false 0002023016 0002023016 2026-08-13 2026-08-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15( d ) of the Securities Exchange Act of 1934 Date of Rep

Turn Therapeutics Inc. (TTRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea030177201ex99-1.htm PRESS RELEASE, DATED AUGUST 12, 2026 Exhibit 99.1 Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results Interim Analysis Supports Expansion of GX-03 Phase 2 Study to a Broader Population of Atopic Dermatitis

Biotech gainers included Zhengye Biotechnology (ZYBT), up about 1,048% after a Nasdaq bid-price noncompliance notice. Advanced Biomed (ADVB) rose over 70% after withdrawing a planned SEC-registered offering. Neuronetics (STIM) gained after naming a new CFO. Armata Pharmaceuticals (ARMP) advanced on Phase 3 AP-SA02 progress. Other movers: Profusa (PFSA), Ridgetech (RDGT), Turn Therapeutics (TTRX).

Turn Therapeutics (TTRX) shares rose 3.8% premarket after expanding its GX-03 Phase 2 atopic dermatitis trial to a broader EASI severity population. The company completed an interim analysis and said efficacy was seen in mild-to-moderate patients (EASI 1.1–7.0), with 71.4% vs 33.3% vehicle achieving Week 4 vIGA-AD success. Final design targets ~120–135 patients; no treatment-related serious AEs reported.

Turn Therapeutics (TTRX) reported interim Phase 2 data for GX-03 in 50 adults with moderate-to-severe atopic dermatitis. According to the company, 92.6% of GX-03 patients achieved EASI-50 at Week 4 vs 65.2% with vehicle; EASI-90 was 44.4% vs 30.4% at Week 4 and 51.9% vs 34.8% at Week 8. No treatment-related serious adverse events were reported.

Turn Therapeutics (TTRX) rose over 20% after interim Phase 2 results for GX-03 in atopic dermatitis, with 92.6% achieving EASI-50 at 4 weeks. Conexeu (CNXU) gained ~19% on preclinical B.R.E.A.S.T. bioprinting progress. Rallybio (RLYB) jumped on plans to acquire Avenzo via a $215M investment. LIXTE (LIXT) surged on an AI energy pivot; Quanterix (QTRX) rose on insider SEC filing.

Turn Therapeutics has secured up to $25 million in growth capital financing from Avenue Capital Group to advance its clinical programs for atopic dermatitis and onychomycosis, with an immediate $7 million tranche. The funding is expected to extend the company's financial runway through the mid-year readout of its Phase 2 trial for atopic dermatitis and support preparations for registrational trials of its lead asset, GX-03. Additional funds are contingent on achieving specific clinical and corporate milestones.

Turn Therapeutics announced corporate and pipeline updates and its 2026 outlook ahead of the 44th Annual J.P. Morgan Healthcare Conference. The company is on track with its Phase 2 trial of GX-03 for atopic dermatitis, expecting interim and topline data in the first half of 2026. Turn Therapeutics also expanded its vaccine pipeline to include an intranasal influenza candidate and anticipates near-term revenue generation in 2026 from its commercial partnership with Medline in wound care.

LOS ANGELES, Nov. 11, 2025 ( GLOBE NEWSWIRE ) -- Turn Therapeutics Inc. ( NASDAQ:TTRX ) , a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, today announced that Chief Executive Officer, Brad Burnam, spoke with Dr. Robert Redfield, ...

Turn's Topical IL36/IL31 Inhibitor Named Alongside Other Phase 2 & 3 Candidates from Amgen, Sanofi, Leo Pharma, Apogee Therapeutics, and Nektar Therapeutics Turn's Topical IL36/IL31 Inhibitor Named Alongside Other Phase 2 & 3 Candidates from Amgen, Sanofi, Leo Pharma, Apogee Therapeutics, and ...